Display options
Cite
Quinn SD, Vedelago J, Regan L, et al. Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study. J Ther Ultrasound. 2013;1:20doi: 10.1186/2050-5736-1-20.
Quinn, S. D., Vedelago, J., Regan, L., & Gedroyc, W. M. (2013). Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study. Journal of therapeutic ultrasound, 120. https://doi.org/10.1186/2050-5736-1-20
Quinn, Stephen Derek, et al. "Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study." Journal of therapeutic ultrasound vol. 1 (2013): 20. doi: https://doi.org/10.1186/2050-5736-1-20
Quinn SD, Vedelago J, Regan L, Gedroyc WM. Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study. J Ther Ultrasound. 2013 Oct 01;1:20. doi: 10.1186/2050-5736-1-20. eCollection 2013. PMID: 25512863; PMCID: PMC4265952.
Copy Download .nbib Format: NLM
Share it on

J Ther Ultrasound. 2013 Oct 01;1:20. doi: 10.1186/2050-5736-1-20. eCollection 2013.

Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study.

Journal of therapeutic ultrasound

Stephen Derek Quinn, John Vedelago, Lesley Regan, Wladyslaw M Gedroyc

Affiliations

  1. Department of Obstetrics and Gynecology, St. Mary's Hospital, Imperial College London, South Wharf Road, London, UK.
  2. Deparment of Radiology, St. Mary's Hospital, Imperial College London, Praed Street, London, UK.

PMID: 25512863 PMCID: PMC4265952 DOI: 10.1186/2050-5736-1-20

Abstract

BACKGROUND: This research investigates whether modifications to the magnetic resonance-guided focused ultrasound ablation of uterine fibroid (MRgFUS) system used resulted in improved treatment volumes of uterine fibroids, while maintaining safety.

METHODS: This study is a prospective cohort analysis of 34 women undergoing the ExAblate 2100 MRgFUS treatment for their uterine fibroids.

RESULTS: The percentage of non-perfused volume (NPV) achieved with the ExAblate 2100 system was 54.92% compared with 50.49 % with the ExAblate 2000 system over the preceding year (p = 0.543). The ExAblate 2100 system resulted in a greater NPV in hyper-intense fibroids compared with the ExAblate 200 system (43.20% versus 36.33%, p = 0.005). There have been no recorded hospital admissions, no skins burns, and no reported major adverse events since the introduction of this new system.

CONCLUSION: Overall, the new system has thus far shown an encouraging safety record and an improvement in non-perfused volumes achieved, especially in hyper-intense fibroids.

Keywords: Leiomyoma; Magnetic resonance-guided focused ultrasound; Uterine fibroids

References

  1. Hum Reprod. 2012 Dec;27(12):3425-31 - PubMed
  2. Lancet. 1986 Feb 8;1(8476):307-10 - PubMed
  3. Ultrasound Obstet Gynecol. 2009 Nov;34(5):579-83 - PubMed
  4. Best Pract Res Clin Obstet Gynaecol. 2008 Aug;22(4):749-60 - PubMed
  5. Fertil Steril. 2006 Jan;85(1):22-9 - PubMed
  6. Fertil Steril. 2010 Jun;94(1):331-4 - PubMed
  7. J Vasc Interv Radiol. 2011 Dec;22(12):1747-50 - PubMed

Publication Types